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Abstract
Background: Driving under the influence of marijuana is a serious traffic safety concern in the United States. Delta
9-tetrahydrocannabinol (THC) is the main active compound in marijuana. Although blood THC testing is a more
accurate measure of THC-induced impairment, measuring THC in oral fluid is a less intrusive and less costly method
of testing.
Methods: We examined whether the oral fluid THC test can be used as a valid alternative to the blood THC test
using a sensitivity and specificity analysis and a logistic regression, and estimate the quantitative relationship
between oral fluid THC concentration and blood THC concentration using a correlation analysis and a linear
regression on the log-transformed THC concentrations. We used data from 4596 drivers who participated in the
2013 National Roadside Survey of Alcohol and Drug Use by Drivers and for whom THC testing results from both
oral fluid and whole blood samples were available.
Results: Overall, 8.9% and 9.4% of the participants tested positive for THC in oral fluid and whole blood samples,
respectively. Using blood test as the reference criterion, oral fluid test for THC positivity showed a sensitivity of 79.
4% (95% CI: 75.2%, 83.1%) and a specificity of 98.3% (95% CI: 97.9%, 98.7%). The log-transformed oral fluid THC
concentration accounted for about 29% of the variation in the log-transformed blood THC concentration. That is,
there is still 71% of the variation in the log-transformed blood THC concentration unexplained by the log-transformed
oral fluid THC concentration. Back-transforming to the original scale, we estimated that each 10% increase in the oral
fluid THC concentration was associated with a 2.4% (95% CI: 2.1%, 2.8%) increase in the blood THC concentration.
Conclusions: The oral fluid test is a highly valid method for detecting the presence of THC in the blood but cannot be
used to accurately measure the blood THC concentration.
Keywords: Blood samples, Cannabis, Delta 9-tetrahydrocannabinol, Driving under the influence, Marijuana, Oral fluid
samples
Background
Marijuana is a commonly used drug in the United
States. In 2015, there were an estimated 22.2 million
Americans aged 12 years or older reporting current
marijuana use and 19.8% (about one in every five) young
adults aged 18 to 25 years were current users (Center
for Behavioral Health Statistics and Quality 2016). Ex-
perimental and epidemiological studies showed that
recent marijuana use is associated with decreased driv-
ing performance—e.g., decreased reaction time, reduced
lateral control, driving slower speeds, and impairment of
psychomotor skills—and thus increased motor vehicle
crash risk (Brady and Li 2013; Brady and Li 2014;
Hartman and Huestis 2013; Chihuri et al. 2017). Driving
under the influence (DUI) of marijuana is of increasing
concern in the United States (Berning et al. 2015; Li
et al. 2016; Davis et al. 2016; Johnson et al. 2012;
Edwards et al. 2017). The annual number of fatal auto-
mobile crashes attributable to impaired driving has been
on the rise and marijuana is the most frequently
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detected non-alcohol drug in drivers in the United States
(Brady and Li 2013; Brady and Li 2014; Romano and
Voas 2011; Tefft et al. 2016; Downey et al. 2013;
Hartman et al. 2015; Lennéa et al. 2010; Li et al. 2012).
From 1999 to 2010, the prevalence of marijuana de-
tected among drivers involved in fatal car crashes tripled
from 4.2% to 12.2% (Brady and Li 2014).
Delta 9-tetrahydrocannabinol (THC) is the primary psy-
choactive compound in marijuana and its presence in blood
samples is viewed as an indicator of recent (1–8 h after
smoking or oral intake) marijuana use (Karschner et al.
2012; Hartman et al. 2016; Jones et al. 2008). Because blood
THC test is a more accurate measure of THC-induced im-
pairment (Hartman et al. 2016; Grotenhermen et al. 2007),
many US states use blood THC concentrations as the gold
standard for determining marijuana-related DUI (Center
for Behavioral Health Statistics and Quality 2016; Berning
et al. 2015). Different cut-off points of blood THC concen-
trations have been proposed for establishing per se laws,
which make operating a motor vehicle a criminal offense
for an individual if he or she has a specific amount of drug
or metabolite in his or her body. This threshold concentra-
tion is a legal limit, and exceeding this threshold serves as
proof of legal impairment (Grotenhermen et al. 2007;
Wong et al. 2014; National Conference of State Legislatures
2017). Currently, 20 states have established per se limit laws
on marijuana-impaired driving, with four states using 5
nanograms per milliliter (ng/ml) as the threshold for THC
and the others having zero tolerance (National Conference
of State Legislatures 2017).
Compared to collecting whole blood samples, measur-
ing THC in oral fluid is a less intrusive and less costly
method of testing (Grotenhermen et al. 2007; Bosker
and Huestis 2009; Drummer 2005; Drummer 2006). Al-
though no accurate predictive function has been estab-
lished between the oral fluid THC concentration and the
whole blood THC concentration, studies have showed a
correlation between these two test results (Lee and
Huestis 2014). Hence oral fluid THC testing has poten-
tial utility as a standard screening tool for detecting
marijuana-related DUI (Gjerde et al. 2014; Langel et al.
2014; Gjerde et al. 2015; Edwards et al. 2017). In this
study, we assess the validity of oral fluid THC test versus
blood THC test using sensitivity and specificity analysis
and a logistic regression, and estimate the quantitative
relationship between the oral fluid THC concentration
and the blood THC concentration using a correlation




Data for this study came from the 2013 National Road-
side Survey of Alcohol and Drug Use by Drivers (NRS)
conducted by the National Highway Traffic Safety
Administration, the National Institute on Drug Abuse,
and the Insurance Institute for Highway Safety. The aim
of the NRS was to estimate the prevalence of driving
under the influence of alcohol and/or drugs in the
United States (Berning et al. 2015). The first NRS was
conducted in 1973; since then, it has been conducted in
1986, 1996, 2007 and 2013. The 2013 NRS was a national
field survey based on voluntary and anonymous random
stops of non-commercial drivers at 300 locations across
the 48 contiguous states (Kelley-Baker et al. 2016). The
sample was selected using multistage sampling method
and only verbally consented drivers were included in the
survey. Data were collected from drivers in 60 locations
during the hours of 9:30 AM to 11:30 AM and 1:30 PM to
3:30 PM on Fridays and another 240 locations 10 PM to
12 AM and 1 AM to 3 AM on Fridays and Saturdays from
June 7, 2013 through March 30, 2014. Detailed informa-
tion on the 2013 NRS methodology can be found else-
where (Kelley-Baker et al. 2016).
The survey included questions on driver demographic
characteristics such as age and race, drinking and drug use
habits such as time of last marijuana use, trip information
including trip origin and destination, seatbelt usage, and ve-
hicle information such as number of passengers and vehicle
type. All information was collected from the drivers via
electronic tablet except for gender, which was recorded via
officer observation. In addition, breath alcohol, oral fluid al-
cohol, and oral fluid drug concentration tests were adminis-
tered and whole blood specimens were collected during the
survey process (Kelley-Baker et al. 2016). Among 11,100
eligible drivers, 8802 (79.3%) voluntarily participated in the
2013 NRS, and 4669 (42.1%) consented to provide both
blood and oral fluid samples for drug and alcohol testing.
For this study, we used the data from 4596 drivers aged
16 years and older with both blood and oral fluid THC con-
centration test results. Compared to all the drivers who par-
ticipated in the 2013 NRS, these 4596 drivers had a similar
age distribution and proportion of females, but included
fewer whites (59.1% vs. 62.0%) and were more likely to re-
port either never having used marijuana or the last time of
use to be beyond a year (79.4% vs. 69.5%).
Measures of interest
In the 2013 NRS, 1 ml (ml) of oral fluid sample and
10 ml of whole blood specimen were collected from
each consented driver. The presence of THC in oral
fluid and whole blood samples were first screened by
Enzyme-linked Immunosorbent Assay (ELISA) (Moore
et al. 2006). The minimum detectable screening concen-
tration of THC in oral fluid, as measured by ELISA, was
4 ng/ml. Samples screened as having THC concentra-
tions ≥4 ng/ml were further tested using liquid/gas chro-
matography and mass spectrometry (LC/MS/MS)
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technology with a minimum detectable THC concentra-
tion of 2 ng/ml in oral fluid. A similar screening and
confirmation process was carried out for measuring
THC concentrations in whole blood samples. The mini-
mum detectable concentration of THC in blood was
10 ng/ml using the ELISA screening test and 1 ng/ml
using the LC/MS/MS confirmation test. Results from
the LC/MS/MS test were recorded as the final results
for both oral fluid and blood samples (Kelley-Baker et al.
2016).
Defining positivity of THC in blood and oral fluid samples
We defined a blood THC test as positive if the THC
concentration was greater than 0 ng/ml (or ≥ 1 ng/ml)
in the whole blood sample for two reasons. First, it is
the minimum detectable concentration of THC in the
whole blood. Second, it is the cutoff point for establish-
ing per se laws by many states (National Conference of
State Legislatures 2017). This cut-off was consistent
with the NRS methodology (Kelley-Baker et al. 2016).
To define positivity for oral fluid THC test that best
predicted positivity of THC in blood, we dichotomized
the oral fluid THC concentrations using a series of cut-
offs greater than or equal to the minimum detectable
concentration (≥ 2 ng/ml, ≥ 3 ng/ml, etc.). We con-
ducted a series of logistic regression of the binary blood
THC test (positive vs. negative) on the binary oral fluid
THC test defined by each cut-off value. Each logistic
regression model controlled for driver age (16–20 years,
21–34 years, 35–54 years, and 55 years or older), gen-
der (female or male), race (white, black, or other), time
of last marijuana use (beyond a year/never, over a
month, within the past month to 2 days, or in the past
24 h), and blood alcohol concentration (BAC; 0 mg/dl,
1–39 mg/dl, and 40 or more mg/dl). We used a random
sample with 80% of the 2013 NRS data to build logistic
regression models and the remaining 20% to calculate
accuracy defined as the proportion of true positive or
true negative cases and area under receiver operating
characteristic curve (AUC) (Robin et al. 2011). Higher
values of accuracy and AUC indicate better predict-
ive ability of the dichotomized oral fluid THC con-
centrations at the selected cut-off in distinguishing
between positive and negative blood THC tests. The
highest accuracy (0.966) was found in the cut-off
values of ≥ 2 ng/ml and ≥ 3 ng/ml for oral fluid test.
Although the cut-off value of ≥ 3 ng/ml yielded a
slightly greater AUC (0.865) than the cut-off value of
≥ 2 ng/ml (0.863), we defined positivity of THC in
oral fluid using ≥ 2 ng/ml because it was the mini-
mum detectable THC concentration (i.e., same as
using > 0 ng/ml) and was consistent with the NRS
methodology (Kelley-Baker et al. 2016).
Statistical analysis
We first calculated positive rates of THC in both blood
and oral fluid samples and computed sensitivity and spe-
cificity of the oral fluid THC test in predicting the posi-
tivity of blood THC. The analysis was conducted using
the whole sample and then stratified by driver
characteristics.
We then fit three logistic regression models of the posi-
tivity in blood THC on oral fluid THC, which was in-
cluded in the model using both a binary covariate (> 0 ng/
ml vs. = 0 ng/ml) and the natural-log of the continuous
THC concentration. For samples with 0 ng/ml oral fluid
THC concentrations, 0.5 ng/ml was used to enable
natural-log transformation. The first model assessed the
crude association. The second model adjusted for BAC
and time of last marijuana use. The third model further
controlled for demographic characteristics of driver age,
gender, and race. We tested the interaction terms between
BAC and oral fluid THC test, but the interaction terms
were excluded from the final models because they were
not statistically significant.
We also examined the association between the con-
tinuous blood THC concentration and the continuous
oral fluid THC concentration among drivers with posi-
tive THC in either blood or oral fluid. We calculated
Pearson correlation coefficient between these two con-
centrations in both the original and natural-log trans-
formed scales. We then built linear regression models of
the natural-log transformed blood THC concentration
on the natural-log transformed oral fluid THC concen-
tration. Similar to the logistic regression, we used a value
of 0.5 ng/ml for 0 ng/ml THC concentrations to enable
natural-log transformation and considered both the un-
adjusted and the two adjusted models.
Finally, we conducted two sensitivity analyses. In the
first sensitivity analysis, we multiply imputed the missing
data on gender and time of last use of marijuana using
the multiple imputation by chained equations algorithm
to create complete data for the covariates in the adjusted
models (Van Buuren and Groothuis-Oudshoorn 2011).
The second sensitivity analysis accounted for complex
survey design in the 2013 NRS survey. Analyses were
conducted using R version 3.2.4 (R Development Core
Team, Vienna, Austria).
Results
Figure 1 shows the percentages of positive and negative
blood THC tests at different oral fluid THC concentra-
tions (0, 2, 3, 4, and ≥5 ng/ml). Most of the drivers with
fluid THC concentrations under the minimum detection
limit (< 2 ng/ml or = 0 ng/ml) were negative in the blood
THC tests. The percentage of positivity in blood THC
increased as the concentration of oral fluid THC
increased.
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Table 1 provides the positive rates of THC in blood and
oral fluid samples as well as the sensitivity and specificity
of the positivity of oral fluid THC in predicting the posi-
tivity of blood THC. Overall, 9.4 and 8.9% of the samples
tested positive for THC in blood and oral fluid, respect-
ively, yielding a sensitivity of 79.4% with a 95% confidence
interval (CI) (75.2%, 83.1%) and a specificity of 98.3%
(95% CI: 97.9%, 98.7%) for the oral fluid test in predicting
positivity in blood THC. The oral fluid test had the high-
est sensitivity among drivers with positive BAC but lowest
sensitivity among drivers older than 55 years of age. The
specificity was higher than 90% in all groups, except
drivers with the last use of marijuana in the past 24 h
(66.7%, 95% CI: 52.1%, 79.2%).
Estimated odds ratios (ORs) and associated 95%
confidence intervals from the logistic regression of
the positivity in blood THC given oral fluid THC are
presented in Table 2. Both the unadjusted and ad-
justed regression models showed that positivity in oral
fluid THC was significantly associated with positivity
in blood THC. After adjusting for driver BAC, last
time use of marijuana and demographic characteris-
tics, having a positive oral fluid THC test was associ-
ated with an 11-fold increase in the odds of having a
positive blood THC test. The odds of positivity in
blood increased as the concentration of the oral fluid
THC increased, where every 10% increase in oral
fluid THC was associated with an additional 6% (95%
CI: 5.1%, 7.7%) increase in the odds of positive blood
THC. Other covariates significantly associated with
positivity in blood THC included BAC, race, and last
time use of marijuana. By including BAC and last
time use of marijuana, the predictive ability of the lo-
gistic regression improved with AUC increased from
0.87 (95% CI: 0.82, 0.91) to 0.95 (95% CI: 0.91, 0.98).
Figure 2 shows the scatter plots and estimated Pearson
correlation coefficients for continuous THC concentra-
tion in blood and in oral fluid on both the untrans-
formed and log-transformed scales. Log-transformed
values were associated with a higher Pearson correlation
coefficient (0.53 vs. 0.37), indicating a stronger linear as-
sociation and as such, we used these transformed values
in linear regression models. The linear regression models
examining the association between the natural-log blood
THC concentration and the natural-log oral fluid THC
concentration shows that a 10% increase in oral fluid
THC concentrations was associated with a 2.4% (95%
CI: 2.1%, 2.8%) increase in blood THC concentrations
(Table 3). Drivers who used marijuana in the past 24 h
had a higher blood THC concentration than drivers who
never used marijuana or who last used marijuana a year
or more prior to testing. We compared the point esti-
mates and 95% confidence intervals of the coefficients in
Tables 2 and 3 to those with multiple imputation and
survey weighting adjustment and found that the results
were consistent.
Fig. 1 Percentages of Drivers with Positive and Negative Blood THC at Different Levels of Oral Fluid THC Concentration using the Data of Drivers
Aged 16 Years and Older with both Blood and Oral Fluid THC Test Results in the 2013 NRS (n = 4596)
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Discussion
This study showed that oral fluid tests are reasonably ac-
curate in detecting blood THC positivity with a 79.4% of
sensitivity and 98.3% of specificity. The sensitivity and spe-
cificity are similar across subgroups of drivers with differ-
ent characteristics, except for drivers older than 55 years
of age (a low sensitivity of 54.6%) and drivers who re-
ported using marijuana in the past 24 h (a low specificity
of 66.7%). Positivity in oral fluid THC is strongly associ-
ated with positivity in blood THC (OR = 11.36). Informa-
tion on BAC and last time use of marijuana may be used
to enhance our ability in predicting the positivity in blood
THC. These results suggest that the oral fluid test is a
valid method for detecting the presence of THC in the
blood. Our study reaffirms the findings reported by
Kelley-Baker et al. (2016).
There exists a fairly strong linear relationship between
the log-transformed oral fluid THC concentrations and
the log-transformed blood THC concentrations (Pearson
correlation coefficient = 0.53, p = < 0.001). This finding
adds to the existent evidence that oral fluid THC is associ-
ated with blood THC (Langel et al. 2014; Gjerde et al.
2014). We improved the prediction models by including
covariates and using the log-transformation to yield a bet-
ter linear correlation. However, given that oral fluid THC
concentration only explained 29% of variation in the blood
THC concentration, it is not advisable to derive blood
THC concentrations from oral fluid THC concentrations.
We defined blood THC positivity using the detection
limit (≥ 1 or > 0 ng/ml) as the cut-off. Alternatively, we
conducted a sensitivity analysis by using other cut-off
points with > 1, 2, 3, and 5 ng/ml. Because there was no
driver with a blood THC concentration of 1 ng/mL in
the study sample, the sensitivity-specificity analysis using
> 1 ng/ml as the cut-point yielded the same results as
that using > 0 ng/ml. When a cut-point of > 2 ng/ml was
used, the sensitivity improves significantly from 79.4% to
91.7% but the specificity reduces from 98.3% to 95.3%
when the positivity in the oral fluid sample was defined
as > 0 ng/ml. This sensitivity analysis supports our con-
clusion that the oral fluid test is a valid alternative to de-
tect the positivity of THC in the blood. However, given
that many states have adopted a zero-tolerance policy
toward drugged driving, the analysis using the cut-off
Table 1 Percentages of Drivers with THC Positivity in Blood and Oral Fluid and Sensitivity-Specificity Analysis of the Oral Fluid Test
using the Blood Test as the Reference Criterion. The Analyses were performed for All Drivers and Stratified by Driver’s Characteristics






All 4596 431 (9.4) 411 (8.9) 79.4 (75.2, 83.1) 98.3 (97.9, 98.7)
Age (years)
16–20 479 76 (15.9) 75 (15.7) 81.6 (71.0, 89.6) 96.8 (94.6, 98.3)
21–34 1909 241 (12.6) 233 (12.2) 80.1 (74.5, 84.9) 97.6 (96.8, 98.3)
35–54 1491 92 (6.2) 88 (5.9) 81.5 (72.1, 88.9) 99.1 (98.4, 99.5)
≥ 55 717 22 (3.1) 15 (2.1) 54.6 (32.2, 75.6) 99.6 (98.7, 99.9)
Gender a
Female 1980 143 (7.2) 128 (6.5) 74.1 (66.1, 81.1) 98.8 (98.2, 99.3)
Male 2597 282 (10.9) 279 (10.7) 82.3 (77.3, 86.5) 98.0 (97.3, 98.5)
Race
White 2718 186 (6.8) 173 (6.4) 74.7 (67.9, 80.8) 98.7 (98.1, 99.1)
Black 1015 181 (17.8) 182 (17.9) 86.7 (80.9, 91.3) 97.0 (95.6, 98.0)
Other 863 64 (7.4) 56 (6.5) 71.9 (59.2, 82.4) 98.8 (97.7, 99.4)
Last time use of marijuana b
Beyond a year/Never 3651 106 (2.9) 107 (2.9) 72.6 (63.1, 80.9) 99.2 (98.8, 99.4)
Over a month 294 51 (17.3) 50 (17.0) 84.3 (71.4, 93.0) 97.1 (94.2, 98.8)
Past month/2 days 279 98 (35.1) 87 (31.2) 77.6 (68.0, 85.4) 93.9 (89.4, 96.9)
Past 24 h 209 158 (75.6) 148 (70.8) 82.9 (76.1, 88.4) 66.7 (52.1, 79.2)
Blood alcohol concentration (ng/dl)
0 4485 405 (9.0) 379 (8.5) 78.3 (73.9, 82.2) 98.5 (98.1, 98.8)
1–39 34 12 (35.3) 14 (41.2) 100.0 (73.5, 100) 90.9 (70.8, 98.9)
40+ 77 14 (18.2) 18 (23.4) 92.9 (66.1, 99.8) 92.1 (82.4, 97.4)
a 19 missing data on sex
b 163 missing data on last time use of marijuana
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Table 2 Estimated Odds Ratios (OR) and 95% Confidence Intervals (CI) in Adjusted and Unadjusted Logistic Regression Models for
THC Positivity in Blood given Oral Fluid Concentration (ng/ml), Continental United States, Nighttime Weekend and Daytime Friday,
2013–2014
Model 1 (n = 4596) Model 2 (n = 4433) Model 3 (n = 4415)
OR (95% CI) OR (95% CI) OR (95% CI)
Positive oral fluid test result 28.46 (13.86, 58.46) 12.10 (5.15, 28.41) 11.36 (7.32, 17.65)
Log(oral fluid THC) (log-ng/ml) 1.82 (1.48, 2.24) 1.93 (1.51, 2.47) 1.91 (1.68, 2.17)
Blood alcohol concentration (ng/dl)
0 Ref Ref
1–39 0.88 (0.20,3.82) 0.85 (0.39, 1.82)
40+ 0.19 (0.05, 0.72) 0.19 (0.10, 0.38)
Last time used marijuana
Over a year/Never Ref Ref
Over a Month 3.87 (2.26, 6.61) 3.91 (2.95, 5.16)
Past 2 days to a month 8.78 (5.40, 14.26) 8.78 (6.81, 11.33)
Past 24 Hours 25.16 (14.26, 44.41) 26.44 (19.64, 34.59)
Age (years)
16–20 Ref
21–34 1.27 (0.96, 1.68)
35–54 1.16 (0.84, 1.59)
≥ 55 0.96 (0.63, 1.45)
Gender (Male vs. Female) 0.99 (0.81, 1.20)
Race
Black Ref
White 0.57 (0.46, 0.71)
Other Race 0.69 (0.52, 0.91)
AUC (95% CI) 0.87 (0.82, 0.91) 0.94 (0.91, 0.97) 0.95 (0.92, 0.98)
Fig. 2 Scatter Plots of THC Concentrations in Blood and Oral Fluid: (a) Original Scale and (b) Log-transformation (replacing zero values with 0.5),
among Driver with Non-zero Values in either Blood or Oral Fluid (n = 500)
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point of > 0 ng/ml to define blood THC positivity pro-
vides the most relevant results for assessing the validity
of using oral fluid test as a screening tool for detecting
marijuana-impaired DUI.
We then identified optimal cut-off concentration in oral
fluid that provided the highest possible diagnostic accuracy
for predicting positivity of THC in blood using accuracy
and AUC. We found that a cut-off value of ≥ 2 and ≥ 3 ng/
ml in oral fluid achieved the best diagnostic accuracy. We
chose to use the cut-off value of ≥ 2 ng/ml (same as using
> 0 ng/ml) because it is also the minimum detectable level
in the oral fluid sample. This is consistent with other stud-
ies using a cut-off value of ≥ 2 ng/ml (Kelley-Baker et al.
2016; Verstraete 2005), although a cut-off of 38 ng/ml was
used in a population with low prevalence of drugs use
(Gjerde et al. 2014).
It is worth noting that less than half of the eligible
drivers (41.4%) consented to provide both whole blood
and oral fluid samples and these consenting drivers were
less likely to be white and report using marijuana recently
than those who refused to provide specimens. Therefore,
our study results are potentially susceptible to bias. Driver
age, race and last time use of marijuana were reported by
the drivers via electronic tablet and thus can also be sub-
ject to bias. Moreover, the measurement of blood and oral
fluid THC concentrations was limited by the detection
limits of ELISA and LC/MS/MS screening and confirm-
ation tools. With the improvement of the detection limits
in both oral fluid and whole blood samples in the future,
we expect to observe a higher degree of agreement in the
positivity of THC tests between the oral fluid and blood
samples. Although THC is the most important psycho-
active constituent of cannabis, there are other chemical
compounds in marijuana that may impair driving safety.
Currently, marijuana test based on oral fluids is limited
primarily to detecting THC only.
Notwithstanding, the 2013 NRS provided valuable data
in assessing the validity of the oral fluid test as a less in-
vasive and less costly alternative to blood test in detect-
ing the presence of THC in the blood. Further research
is needed to better understand the relationship between
blood and oral fluid THC concentrations and to develop
a more reliable algorithm for calculating blood THC
concentrations based on oral fluid testing results.
Table 3 Estimated Regression Coefficients (β) and 95% Confidence Intervals (CI) in Adjusted and Unadjusted Linear Regression
Models of the Log-transformed Blood THC (ng/ml) on Log-transformed Oral Fluid THC (ng/ml) among Drivers with Non-zero THC
Concentrations in either Blood or Oral Fluid, Continental United States, Nighttime Weekend and Daytime Friday, 2013–2014
Model 1 (n = 500) Model 2 (n = 478) Model 3 (n = 472)
β (95%CI) β (95%CI) β (95%CI)
Intercept 0.14 (0.01, 0.26) 0.00 (−0.17, 0.17) −0.01 (−0.31, 0.28)
Log of Oral Fluid THC Concentration (ng/ml) 0.25 (0.22, 0.29) 0.25 (0.21, 0.29) 0.25 (0.22, 0.29)
Blood Alcohol Concentration (ng/dl)
0 Ref Ref
1–39 − 0.29 (− 0.77, 0.19) − 0.22 (− 0.72, 0.28)
40+ − 0.18 (− 0.60, 0.25) − 0.15 (− 0.58, 0.27)
Last time use of Marijuana
Over a year/Never Ref Ref
Over a Month 0.15 (−0.13, 0.42) 0.16 (−0.12, 0.44)
Past 2 days to a month 0.22 (−0.01, 0.45) 0.22 (−0.01, 0.46)
Past 24 Hours 0.29 (0.08, 0.49) 0.30 (0.10, 0.51)
Age (years)
16–20 Ref
21–34 0.05 (−0.17, 0.27)
35–54 0.06 (−0.20, 0.33)
≥ 55 −0.13 (− 0.56, 0.30)
Gender (Male vs. Female) −0.12 (− 0.29, 0.06)
Race
Black Ref
White −0.03 (−0.21, 0.15)
Other Race 0.27 (0.01, 0.52)
R2 0.29 0.30 0.31
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Conclusions
Oral fluid test is a highly valid method for detecting the
presence of THC in the blood and thus could be used as a
screening tool for detecting marijuana-related DUI. Al-
though there is a significant linear association between the
log-transformed blood THC concentrations and the log-
transformed oral fluid THC concentrations, log-transformed
oral fluid THC concentrations can explain only 29% of the
variation in log-transformed blood THC concentrations.
Therefore, the oral fluid test is not an accurate method for
estimating THC concentrations in the blood.
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